A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)

Official Summary

This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients

Study Design

• Study Type: INTERVENTIONAL
• Allocation: NON_RANDOMIZED
• Model: PARALLEL
• Masking: NONE
• Enrollment: 57 participants

Interventions

• DRUG: Ceritinib (LDK378)
• DRUG: Nivolumab

Primary Outcomes

• Maximum Tolerated Dose (MTD) and/or Recommended Dose for Expansion (Study Day 42 (6 weeks))
• Overall response rate (ORR) (24 Weeks)

Secondary Outcomes

• Duration of Response (DOR) (24 weeks)
• Disease Control Rate (DCR) (24 weeks)
• Time to Response (TTR) (24 weeks)
• Progression Free Survival (PFS) (24 weeks)
• Overall survival (OS) (24 weeks)

Eligibility Criteria

Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of NSCLC that carries an ALK rearrangement
* Stage IIIB or IV NSCLC or relapsed locally advanced or metastatic NSCLC
* Presence of at least one measurable lesion as defined by RECIST 1.1
* Patients who have received prior chemotherapy, other ALK inhibitors, biologic therapy, or other investigational agents, must have recovered from all toxicities related to prior anticancer therapies to grade ≤1 (CTCAE v 4.03). Patients with grade ≤ 2 peripheral neuropathy or any grade of alopecia, fatigue, nail changes or skin changes are allowed to enter the study
* Patient has a WHO performance status 0-1

Exclusion Criteria:

* Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years
* Patients with an active, known or suspected autoimmune disease
* Unable or unwilling to swallow tablets or capsules
* Patient has other severe, acute, or chronic medical conditions including uncontrolled diabetes mellitus or psychiatric conditions or laboratory abnormalities that in the opinion of the Investigator may increase the risk associated with study participation, or that may interfere with the interpretation of study results

Trial Locations

• Mayo Clinic - Arizona, Scottsdale, Arizona, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Massachusetts General Hospital Thoracic Oncolgoy, Boston, Massachusetts, United States
• Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
• Novartis Investigative Site, Heidelberg, Victoria, Australia
• Novartis Investigative Site, Leuven, Vlaams Brabant, Belgium
• Novartis Investigative Site, Toronto, Ontario, Canada
• Novartis Investigative Site, Hong Kong, Hong Kong
• Novartis Investigative Site, Milan, MI, Italy
• Novartis Investigative Site, Modena, MO, Italy
• ...and 2 more locations

More ALK-positive NSCLC Trials

View all ALK-positive NSCLC clinical trials